In a potential setback for Roche (RHHBY), five patients taking its new Hemlibra hemophilia treatment have died, raising uncertainty about the safety of the medication, even though the company maintained its drug did not cause any of the deaths.
Over the past two years, one patient died during a late-stage clinical trial and the others died while taking Hemlibra as part of a compassionate use program, which provides access to experimental medicines before regulatory approval.
About the Author Reprints
May I observe that people wonder wht ‘PHARMA” is against these right-to-try initiatives? How about ‘stuff happens?” – “Over the past two years, two patients died while taking Hemlibra as part of a compassionate use program, which provides access to experimental medicines before regulatory approval.”
And so Roche made the drug available and what is their reward? I’m not trying to deify them but nothing complicated is ever a zero sum game. The fact of there events is and will be counted against them. I would say how dumb did the US House have to be to pass something like that but …. why ask?